Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02858076 · ClinicalTrials.gov registry record · Phase 2
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
A Phase 2 study of Proliferative Diabetic Retinopathy and Vitreous Hemorrhage, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
- 20
- Study locations
NCT02858076 is a Phase 2 study of Proliferative Diabetic Retinopathy and Vitreous Hemorrhage that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 205 participants, above the 176-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02858076, a Phase 2 study of Proliferative Diabetic Retinopathy and Vitreous Hemorrhage, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
- 20
- Study locations
Study Summary
Although vitreous hemorrhage (VH) from proliferative diabetic retinopathy (PDR) can cause acute and dramatic vision loss for patients with diabetes, there is no current, evidence-based clinical guidance as to what treatment method is most likely to provide the best visual outcomes once intervention is desired. Intravitreous anti-vascular endothelial growth factor (anti-VEGF) therapy alone or vitrectomy combined with intraoperative PRP each provide the opportunity to stabilize or regress retinal neovascularization. However, clinical trials are lacking to elucidate the relative time frame of visual recovery or final visual outcome in prompt vitrectomy compared with initial anti-VEGF treatment. The Diabetic Retinopathy Clinical Research Network Protocol N demonstrated short-term trends consistent with a possible beneficial effect of anti-VEGF treatment in eyes with VH from PDR, including greater visual acuity improvement and reduced rates of recurrent VH as compared with saline injection. It is possible that a study with a longer duration of follow-up with structured anti-VEGF retreatment would demonstrate even greater effectiveness of anti-VEGF for VH to avoid vitrectomy and its attendant adverse events while also improving visual acuity. On the other hand, advances in surgical techniques leading to faster operative times, quicker patient recovery, and reduced complication rates may make prompt vitrectomy a more attractive alternative since it results in the immediate ability to clear hemorrhage and to perform PRP if desired, often as part of one procedure. This proposed study will evaluate the safety and efficacy of two treatment approaches for eyes with VH from PDR: prompt vitrectomy + PRP and intravitreous aflibercept injections.
Conditions Studied
Interventions
- DRUG 2-mg Intravitreous Aflibercept Injection
- PROCEDURE Prompt Vitrectomy Plus Panretinal Photocoagulation
Study Locations (20)
California
- Retinal Diagnostic Center - Campbell
- Macula & Retina Institute - Glendale
- Atlantis Eye Care - Huntington Beach
- Loma Linda University Health Care, Department of Ophthalmology - Loma Linda
- Shashi D Ganti, MD PC - Porterville
Florida
- Florida Retina Consultants - Lakeland
- Southeast Eye Institute, P.A. dba Eye Associates of Pinellas - Pinellas Park
- Retina Associates of Sarasota - Sarasota
- Retina Associates of Florida, P.A. - Tampa
Georgia
- Emory Eye Center - Atlanta
- Southeast Retina Center, P.C. - Augusta
- Marietta Eye Clinic - Marietta
- Thomas Eye Group - Sandy Springs
Illinois
- Gailey Eye Clinic - Bloomington
- Northwestern Medical Faculty Foundation - Chicago
- University of Illinois at Chicago Medical Center - Chicago
- Carle Foundation Hospital - Urbana
Indiana
- Raj K. Maturi, MD, PC - Indianapolis
- John-Kenyon American Eye Institute - New Albany
Kansas
- Retina Associates, P.A. - Shawnee Mission
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02858076
The ClinicalTrials.gov registry entry for NCT02858076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 176-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (16% higher). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which 2-mg Intravitreous Aflibercept Injection is the first listed.
NCT02858076 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02858076 about?
NCT02858076 is a clinical study titled "Anti-VEGF vs. Prompt Vitrectomy for VH From PDR". Although vitreous hemorrhage (VH) from proliferative diabetic retinopathy (PDR) can cause acute and dramatic vision loss for patients with diabetes, there is no current, evidence-based clinical guidance as to what treatment method is most likely to provide the best visual outcomes once intervention ...
What is the current status of trial NCT02858076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2016-11. Estimated completion is 2020-01.
What conditions does trial NCT02858076 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy, Vitreous Hemorrhage.
What interventions are being tested in trial NCT02858076?
The interventions under investigation include: 2-mg Intravitreous Aflibercept Injection (DRUG), Prompt Vitrectomy Plus Panretinal Photocoagulation (PROCEDURE).
Who is sponsoring clinical trial NCT02858076?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02858076 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
COMPLETED · Phase 3
-
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.